Semaglutide 2 mg
Educational recon guide for a 2 mg Semaglutide research vial and once-weekly unit mapping. Research use only — not Ozempic/Wegovy pens.
Vial size
Same research phases — calculator defaults and unit math match the selected vial strength.
Vial
2 mg
Your BAC water
1 mL
Concentration
2.00 mg/mL
Per unit
~20.0 mcg
Frequency
Once weekly subcutaneous (same weekday)
Route
Subcutaneous
Live reconstitution calculator
Defaults match this guide (2 mg + 1 mL BAC). Change water or dose and the unit tables below update automatically.
Step 1
Reconstitution
Peptide amount in the vial and how much bacteriostatic water you add.
Step 2
Your dose
This guide uses microgram-scale research doses — quick picks are in mcg (100 mcg = 0.1 mg).
Quick select (mcg) — switch units or type any value
Suggested: 30-unit barrel (smallest that fits this draw).
Your draw
Results
Total draw
12.5 units
Volume
0.125 mL
Doses per vial
8
Syringes needed
1
Barrel
30-unit
Fits one syringe?
Yes
30-unit · 0.3 mL
Filled to 12.5 u
Fill one 30-unit U-100 syringe to about 12.5 units (0.125 mL).
Weekly research phases
Units and volumes recompute from your Step 1 concentration (1 mL BAC → 2.00 mg/mL · 20.0 mcg/unit).
Standard titration
Approved chronic weight-management product (Wegovy) titrates 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg once weekly if tolerated. Diabetes products (Ozempic) commonly use lower weekly ceilings. Research powders are not branded pens.
| Phase | Weekly dose | Units | Volume |
|---|---|---|---|
| Weeks 1–4 · 0.25 mg | 250 mcg0.25 mg | 12.5 u | 0.13 mLEducational start |
| Weeks 5–8 · 0.5 mg | 500 mcg0.5 mg | 25 u | 0.25 mL |
| Weeks 9–12 · 1.0 mg | 1 mg1,000 mcg | 50 u | 0.50 mL |
| Weeks 13–16 · 1.7 mg | 1.70 mg1,700 mcg | 85 u | 0.85 mLPrefer 100-unit syringe |
| Weeks 17+ · 2.4 mg | 2.40 mg2,400 mcg | 120 u | 1.20 mLWegovy-style maintenance educational target |
Advanced / higher-end
Faster escalation discussed in research communities — not a clinical recommendation
| Phase | Weekly dose | Units | Volume |
|---|---|---|---|
| Hold at 1.0 mg weekly | 1 mg1,000 mcg | 50 u | 0.50 mLIf higher steps not tolerated / diabetes-product style ceiling discussions |
| Higher educational · 2.0 mg weekly | 2 mg2,000 mcg | 100 u | 1.00 mLSome product labels use 2.0 mg weekly as a step |
Supplies planner
Using the guide’s phase ladder (250 mcg → 500 mcg → 1 mg weekly (phase ladder)) over a 12-week schedule. Set a dose in Step 2 to plan supplies at your own amount.
Your recon
1 mL · 2.00 mg/mL
Dose in plan
Phase ladder
Syringe size
100-unit
Horizon
12-week schedule
Semaglutide 2 mg vials
4 vials
~7 mg mg total peptide over this 12-week schedule at 250 mcg → 500 mcg → 1 mg weekly (phase ladder). Each vial holds 2 mg.
Bacteriostatic water
2 × 3 mL or 1 × 10 mL
1 mL BAC per vial × 4 vials = 4.0 mL total. Buy as 2× 3 mL bottles or 1× 10 mL bottle (whichever you stock).
U-100 insulin syringes (100-unit)
12+ syringes
About one 100-unit syringe per injection for this schedule. Keep a few spares.
Alcohol swabs & sharps
~32 swabs · 1 sharps container
Wipe vial stopper and injection site each time. Dispose needles in a proper sharps container.
Reconstitution steps
- Allow the lyophilized 2 mg Semaglutide vial and bacteriostatic water to reach room temperature.
- Draw 1.0 mL bacteriostatic water (default for this guide).
- Inject BAC slowly down the inner wall of the vial — avoid blasting the powder cake.
- Gently swirl or roll until the solution is clear. Do not shake hard (foaming).
- Label with recon date and concentration (e.g. "2.0 mg/mL").
- Refrigerate at 2–8 °C (35–46 °F), protected from light. Prefer using a reconstituted multi-dose vial within ~28 days with sterile technique.
Storage
Lyophilized
Keep dry powder cold and dark when possible (−20 °C / −4 °F preferred for long-term research stock).
Reconstituted
Refrigerate at 2–8 °C (35–46 °F). Avoid freeze–thaw of the working solution. Prefer finishing within ~28 days.
- ·Write recon date and BAC volume on the label.
- ·Protect from light during storage.
- ·Discard if cloudy, particulates, or odd odor appear after reconstitution.
Protocol notes
- ·Once-weekly GLP-1 agonist — titrate slowly for GI tolerability.
- ·Research powders ≠ Ozempic/Wegovy pens.
- ·Research use only.
Research context & considerations
Semaglutide is an approved GLP-1 receptor agonist for T2D and chronic weight management as branded products. Catalog research vials are a separate unregulated channel.
- ·GI effects common during titration.
- ·GLP-1-class label cautions apply (gallbladder, pancreatitis discussions, MTC/MEN2 framing on approved products).
- ·Not FDA-approved as a research-vial consumer product.
- ·Pregnancy out of scope.
Catalog match
Semaglutide (SM2)
2mg x 10 vials · from $20